<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144489">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01746485</url>
  </required_header>
  <id_info>
    <org_study_id>TDE-DU-102</org_study_id>
    <nct_id>NCT01746485</nct_id>
  </id_info>
  <brief_title>Three Times Daily Dosing of UT-15C</brief_title>
  <official_title>A PK Evaluation of Three Times Daily Dosing of UT-15C SR Tablets in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics of three-times daily dosing of UT-15C in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Area under the curve (AUC) from 0-24hrs after 6 days of TID dosing.</measure>
    <time_frame>6 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax, tmax, AUC(0-6), AUC(0-24), AUC(6-12), AUC(12-24) and t1/2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile of UT-15C after a single 0.5mg dose on Day 1</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Day 1: Cmax, tmax, AUC(0-6), AUC(0-24), AUC(0-t), AUC(0-inf), and t1/2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>UT-15C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UT-15C</intervention_name>
    <arm_group_label>UT-15C</arm_group_label>
    <other_name>treprostinil diethanolamine</other_name>
    <other_name>treprostinil diolamine</other_name>
    <other_name>UT-15C SR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Healthy male and female subjects

          -  aged 18-55 years of age;

          -  weight between 50 and 100 kg, with a body mass index (BMI) between 19.0 and 29.9
             kg/m2, inclusive for female subjects and

          -  weight between 50 and 120 kg, with a BMI between 19.0 and 32.0 kg/mÂ², inclusive for
             male subjects.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa Pham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PPD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 10, 2012</lastchanged_date>
  <firstreceived_date>August 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volunteers</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
